<p>
    Immunosuppression Management:
</p>
<p>
    Use of Sirolimus (3–8 ng/mL) may be considered in:
</p>
<ul>
    <li data-list-item-id="edbfab76aa533914ea9eaab74f6428683">
         HCC (within Milan criteria)
    </li>
    <li data-list-item-id="ef1bbd82a650f5d6771a48b5a4c254112">
         CMV infection or reactivation
    </li>
    <li data-list-item-id="e053bd48d6900856d1b48a94bc5fc7f1c">
         CNI neurotoxicity
    </li>
    <li data-list-item-id="e49a2c45cd000955fdac97992b3759cc3">
         Fibrosis
    </li>
    <li data-list-item-id="e2d924fc2700e42e54c625ecfd60cf518">
         Chronic kidney disease
    </li>
    <li data-list-item-id="ebed0aa4047fd3030b0419aa87af20b22">
         Suspected ductopenic rejection
    </li>
    <li data-list-item-id="e1fe5a6eea0b170603cd1938496b1aefe">
         Possibly ABMR
    </li>
</ul>
<p>
    MASH Recipients:
</p>
<ul>
    <li data-list-item-id="e966585bce6f17768300fb232e44db1ed">
         Optimal IS: Myfortic (MYF) + low-dose tacrolimus (Tac)
    </li>
    <li data-list-item-id="e03ce92ee19026730559cd5c121493c25">
         Avoid sirolimus (increases steatosis)
    </li>
    <li data-list-item-id="e583281f9bd6e43fd4788c7137d0901dc">
         Aim for steroid-free regimen
    </li>
    <li data-list-item-id="e91dd7d33cc66c3141d2125640cbd8d19">
         IS adjustment by MYF dose:
        <ul>
            <li data-list-item-id="e8c1c5b54be11fe74ef8eea52952a03e2">
                 MYF 360–540 mg → reduce Tac target by 30%.
            </li>
            <li data-list-item-id="e29bb227cad6775196bfee9cb2c6cdc70">
                 MYF 540–720 mg → reduce Tac target by 50%.
            </li>
        </ul>
    </li>
</ul>
<p>
    Notes for IS Management:
</p>
<ul>
    <li data-list-item-id="eb77e14d44800d92f64105046d176a930">
         Alternatives to conventional tac:
        <ul>
            <li data-list-item-id="e668b50dd374ea9d4e8c897f9b667bb19">
                 Sublingual tacrolimus: For dysphagia. Reduce oral dose by 20%
            </li>
            <li data-list-item-id="e1951a5634f5e9ef109cc8745004b266b">
                 <strong>Advagraf</strong>: Once-daily Tac formulation (no dose adjustment if coverage available)
            </li>
            <li data-list-item-id="e8e3f61435e90321ae82f414c469fbaac">
                 <strong>Envarsus</strong>: Requires 30% lower dose than standard Tac
            </li>
        </ul>
    </li>
    <li data-list-item-id="e2a5e70ef09b393417cf568ded8af3db7">
         Steroids: High doses can lower Tac levels
        <ul>
            <li data-list-item-id="e1618d4ecc7b36a1b19fe3ce816fd8f0b">
                 Drug equivalence: 250 mg MMF = 180 mg EC-MPS (MYF).
            </li>
        </ul>
    </li>
    <li data-list-item-id="ed9e85fb0fd47765f4eb193b4a1c26582">
         Cyclosporine (CyA):
        <ul>
            <li data-list-item-id="e014aaaaceaa80fbc92297a18f1770373">
                 May be preferred for PBC post 12 months (lower recurrence risk with ursodiol 15 mg/kg).
            </li>
            <li data-list-item-id="edc2e2bd8c1009ba477401f93f7299ee5">
                 Higher BPAR in first 12 months if used early.
            </li>
        </ul>
    </li>
    <li data-list-item-id="eb44bc940b628b437e99415074c49b1f1">
         Azathioprine (1–2 mg/kg) can replace MYF in patients with IBD.
    </li>
    <li data-list-item-id="e0b673757c8854d848aaef318488fb191">
         Vedolizumab is the preferred biologic in IBD; avoid anti-TNF agents with Tac.
    </li>
    <li data-list-item-id="e3e83d15f6152c6ae4f3d5155b107c0c9">
         Patients on CyA for neurotoxicity: Re-trial Tac after 2–6 months if tolerated.
    </li>
</ul>